Screener
Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Three Months Ended June 30, 2026 | Affordable Medicines (1) | Specialty | Av KARE | Corporateand Other | Total Company |
|---|---|---|---|---|---|
| Net revenue | $489,913 | $149,295 | $156,989 | — | $796,197 |
| Cost of goods sold | 282,684 | 48,265 | 130,740 | — | 461,689 |
| Gross profit | 207,229 | 101,030 | 26,249 | — | 334,508 |
| Selling, general and administrative | 42,367 | 40,095 | 16,913 | 49,347 | 148,722 |
| Research and development | 33,023 | 5,994 | — | — | 39,017 |
| Intellectual property legal development expenses | 2,002 | 85 | — | — | 2,087 |
| Acquisition costs | — | — | — | 7,600 | 7,600 |
| Restructuring and other charges | — | — | — | 554 | 554 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — gross profit?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — gross profit of $207.23M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — gross profit changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — gross profit increased by 14.6% year-over-year, from $180.78M to $207.23M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — gross profit?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — gross profit has grown at a 8.5% compound annual growth rate (CAGR), from $536.04M to $683.92M.
- What does affordable medicines — gross profit mean?
- Calculated as net revenue minus the cost of goods sold for the Affordable Medicines segment, representing the core profitability of the product line before operating expenses. It provides insight into the segment's pricing power and manufacturing cost structure.
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude